Key points from article :
Cellino raised $16 million in seed venture capital.
Induced Pluripotent Stem Cells (iPSCs) reprogrammed to develop into any type of human cell.
Labour-intensive process of inspecting iPSCs in order to manually weed out ones deemed to be of lower quality.
Developing an automated process to generate autologous iPSCs at scale.
AI-guided laser platform to automate and scale autologous cell-and tissue-based therapies.
Machine-learning algorithms to train software to identify both low- and high-quality cells.
Software then controls a laser to destroy the unwanted cells.
“Seed financing enables us to build towards a democratized future for autologous cells and tissues,”- Nabiha Saklayen, CEO of Cellino.
“...to lead the next-generation of personalized regenerative medicines” - Alex Morgan, Partner at Khosla Ventures.
“...promise regenerative and curative therapies for many diseases,” - Ann DeWitt, General Partner at The Engine.
